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introduction and objectives: Continuous antibiotic prophylaxis (CAP) use to prevent 
urinary tract infections (UTI) in infants with prenatal hydronephrosis (HN) remains contro-
versial. Lack of consensus guidelines and diverse practice patterns for postnatal man-
agement of HN highlight the dire need for higher level of evidence studies. Herein, we 
aim to describe the steps from developing a well-defined research question to execute 
a multicentered randomized controlled trial (RCT) to address the issue of CAP use in 
patients with prenatal HN.
Materials and methods: The steps involved were (1) choosing the proper research 
question, (2) survey of practice patterns and establishing clinical equipoise, (3) system-
atic review of the literature, (4) reviewing own practice, (5) longitudinal prospective study, 
(6) pilot study, (7) cost-utility analysis, and (8) definitive RCT (clinical trials registry number: 
NCT01140516). An update of our previous systematic review was conducted using two 
electronic databases and gray literature from 2010 to 2015. Eligibility criteria included 
studies of children <2 years old with postnatally confirmed prenatal HN, receiving CAP 
or not, and reporting on development of UTIs, capturing information on voiding cystoure-
throgram result and HN grade. Full-text screening was conducted by two independent 
reviewers. UTI rates in patients with high-grade HN were compared across different 
study designs. Finally, blinded comparative analysis of UTI rates between placebo and 
treatment groups was carried out using chi-square test.
results: UTI rates in patients with high-grade HN by their respective study design were: 
25% for systematic review, 20% for retrospective study, 21% for prospective and pilot 
studies, and 13% for the definitive RCT thus far. Regardless of the type of study design, 
patients with hydroureteronephrosis had significantly higher (threefold to sixfold) UTI 
rates than those with isolated HN. Our updated systematic review yielded 486 citations, 
of which 9 (n = 1987 infants) observational studies met eligibility criteria.
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inTrODUcTiOn
In utero dilation of the renal collecting system, commonly called 
prenatal or antenatal hydronephrosis (HN), is one of the most 
commonly diagnosed congenital abnormalities, detected in up to 
5% of all pregnancies (1). Physiologic- (i.e., transient) isolated HN 
(so called “ureteropelvic junction obstruction-like” or UPJO-like) 
and vesicoureteral reflux (VUR) are the most frequent etiologies, 
followed by non-refluxing primary megaureter [hydroureterone-
phrosis (HUN)] (1). Infants born with prenatal HN have been 
shown to have a 12-fold higher risk of hospitalization for urinary 
tract infections (UTI), predominantly in the first year of life (2). 
Children with Society of Fetal Urology (SFU) grades III–IV HN 
are at a particularly increased risk, having a much higher incidence 
of UTI when compared to those with lower HN grades (3–6).
The potential benefit of continuous antibiotic prophylaxis 
(CAP) in preventing UTIs is often weighted against the perceived 
modest impact of this intervention, along with concerns of develop-
ing bacterial antibiotic resistance and other theoretical long-term 
adverse effects. As a result, the decision to recommend CAP for 
patients with prenatal HN remains controversial. The American 
Urological Association (AUA), the SFU, and the Canadian 
Urological Association (CUA) all acknowledge that use of CAP for 
UTI prevention in infants with prenatal HN has been based on low 
level of evidence. Consequently, in 2009, the CUA guidelines on 
prenatal HN provided grade D recommendation for CAP use in 
children with this condition (7). Not surprisingly, this lack of high-
quality evidence has resulted in multiple guidelines with varying 
criteria for prescribing CAP. In 2010, the SFU Consensus Statement 
on HN recommended prophylaxis only for infants with high-grade 
HN and those with VUR (8). On the other hand, the AUA guidelines 
suggested the use of CAP for children with asymptomatic VUR 
(i.e., without previous history of UTI) to be optional (9). Given the 
uncertainty regarding CAP use in prenatal HN patients, an effort to 
identify knowledge gaps in the literature and find proper evidence-
based recommendations is well-timed and certainly needed.
As a result, the objective of this review is to describe the steps 
necessary to take an investigator from developing a research 
question to executing a large multicenter randomized controlled 
trial (RCT) aimed at addressing the issue of CAP in newborns 
and infants with prenatal HN.
sTeP 1 – chOOsing The PrOPer 
research QUesTiOn
Interest in a particular topic usually triggers the research process, 
but it is the in-depth familiarity with the subject that helps define 
a certain aspect of care for a study. Questions usually arise out 
of perceived knowledge deficits within that topic. It is important 
to know “where the boundary between current knowledge and 
ignorance lies” (10). To exemplify this concept, Donald Rumsfeld 
coined the term known “knowns,” to highlight things we feel are 
well acknowledged and accepted. For example, we can all agree 
that some children with prenatal HN are at risk and may indeed 
develop febrile UTIs (fUTI). There are also known “unknowns,” 
which refer to things we admit as not known (11). We are uncer-
tain whether CAP reduces the risk of UTIs in patients with pre-
natal HN (although some may dispute it, based on limited data). 
Having such a structured and curious mindset to find gaps in the 
literature is essential to developing a proper research question.
A research question worth pursuing should encompass the 
following aspects, captured in the acronym FINER (10): it should 
be Feasible, i.e., related to a condition that affects an important 
number of patients, and thus, can be subjected to scrutiny with a 
reasonable chance of reaching adequate sample size; be Interesting 
to the scientific community and to the public; be Novel, as grant-
ing agencies are unlikely to fund projects that aim at mirroring 
similar previous studies; be Ethical, an undebatable requirement 
that rightfully obeys the strict guidelines set by research ethics 
boards and declarations on ethical conduction of trials (12); 
and finally, be Relevant to an extent that it will favorably impact 
clinical practice. Prenatal HN fits all these criteria, particularly 
in terms of clinical equipoise and lack of properly conducted 
randomized placebo controlled trials reported in the literature.
sTeP 2 – sUrVeY OF PracTice 
PaTTerns anD esTaBlishing clinical 
eQUiPOise
Clinical equipoise refers to genuine uncertainty among clinicians 
regarding the value or superiority of a therapeutic strategy or 
medical intervention. The clinical dilemma regarding manage-
ment of prenatal HN has been confirmed by recent surveys, all 
showing that the decision to prescribe CAP is heavily influenced 
by provider factors, such as length of years in practice, geo-
graphic location, specialty, along with the severity of upper tract 
dilation. For example, pediatric urologists in practice for more 
than 15 years are less likely to initiate CAP at birth than younger 
practitioners (<15 years) (13). By geographic region, American 
physicians are twice as likely to prescribe CAP when compared to 
their European colleagues, whose prescribing decision was based 
mainly on the prenatal renal pelvis diameter (13). According to a 
French-speaking survey, 23% of pediatric nephrologists and 31% 
of pediatric urologists would start CAP immediately after birth 
conclusion: UTI rates in patients with high-grade HN dropped from 25% in obser-
vational studies to 13% in our RCT. This decline in UTI rate demonstrates that study 
designs lacking strategies to minimize bias are more prone to overestimate treatment 
effects. These findings highlight the importance of conducting methodologically sound 
RCTs to answer clinically meaningful questions, such as the one presented here.
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(8). In contrast, 56% of general pediatricians would routinely 
prescribe CAP for infants with prenatal HN (4). By specialty, 
nephrologists were more likely to prescribe CAP for bilateral 
low-grade HN compared to pediatric urologists (14). The former 
group was also more likely to prescribe CAP for high-grade 
“UPJO-like” HN. Across Canada, only 20% of participating insti-
tutions reported following standardized protocols for postnatal 
management of prenatal HN (14). Similarly, Zanetta et al. also 
documented a wide variation in the use of CAP and indication for 
voiding cystourethrograms (VCUG) among American pediatric 
urologists, radiologists, and obstetricians. According to their 
survey, agreement on duration of follow-up for mild prenatal HN 
is missing (15).
This lack of consensus, leading to different management 
strategies for prenatal HN, coupled with paucity of high-level, 
evidence-based guidelines, compels physicians to rely solely on 
their clinical experience and judgment. As a result, controversy 
is evident among the medical community surrounding the use 
of CAP for infants with prenatal HN, clearly exemplifying the 
principle (and presence) of clinical equipoise.
sTeP 3 – criTical aPPraisal OF 
The liTeraTUre
Lack of consensus guidelines and diverse practice patterns for 
postnatal management of prenatal HN undoubtedly derives from 
conflicting and inconsistent data in the literature. Given these 
discrepancies, we previously published a systematic review with 
the goal of summarizing the latest evidence regarding CAP use in 
prenatal HN patients (5). Thus far, it remains the only published 
meta-analysis focusing on this topic, reviewing 1681 titles and 
abstracts, of which 21 full-text articles including data from nearly 
4000 patients were extracted and analyzed (3, 5, 6, 16–34). Pooled 
UTI rates were six times higher for high-grade HN patients when 
compared to those with low-grade HN, similarly to Lee et  al.’s 
study, which showed that the UTI rate rose from 12% in children 
with grade II HN to 40% in those with grade IV (6). UTI rates 
were equivalent in children with low-grade HN regardless of their 
CAP status (2.2% on CAP vs. 2.8% not on CAP, p = 0.51). On 
the contrary, high-grade HN patients on CAP experienced fewer 
UTIs than those not on antibiotics (14.6 vs. 28.9%, p < 0.01), sug-
gesting that CAP may be beneficial for this patient population. 
The estimated number needed to treat (NNT) was 7, meaning 
that a clinician must offer CAP to 7 patients with high-grade HN 
in order to prevent 1 UTI (5).
As it is the case with any systematic review, the applicability 
of this meta-analysis heavily depends on the quality and validity 
of the included studies (35). The review’s main limitation was the 
inclusion of low- to moderate-quality (76%) observational studies 
(5). Despite the lack of high-quality RCTs on the use of CAP for 
prenatal HN, many clinicians are likely to be influenced or change 
clinical practice based on observational studies alone, which may 
not be ideal. In addition, heterogeneous and inconsistent grading 
of HN severity across studies limited the ability to compare UTI 
rates from all included studies. Lastly, the association between 
UTI and important confounding variables, such as presence of 
VUR, gender, and circumcision status, could not be investigated 
due to the paucity of reported data. Nevertheless, despite these 
limitations, this systematic review has reflected the most compre-
hensive review of the literature on the use of CAP for prevention 
of UTIs in children with prenatal HN thus far and sets the stage 
for further exploring the topic.
In order to update the previous systematic review on prenatal 
HN with studies published from 2010 to 2015, we conducted a 
comprehensive search of EMBASE and MEDLINE databases, 
including key search MeSH terms to reflect the following sub-
jects: (1) HN, (2) prenatal, (3) antibiotics prophylaxis, and (4) 
UTI. Articles were screened in duplicate based on the following 
eligibility criteria: (1) primary diagnosis of prenatal HN, (2) all 
subjects aged <2 years, (3) intervention arms included CAP, no 
treatment, or both, (4) reported rate of UTI, (5) reported number 
of patient who underwent VCUG, and (6) HN grade according 
to the SFU classification and/or anteroposterior diameter (APD) 
of the renal pelvis. Case reports, case series with <10 subjects, 
and review articles were excluded. After screening the title and 
abstracts of 486 hits, 39 citations were reviewed in full-text and 
their references were hand searched. Of the 39 full-texts reviewed, 
9 observational studies met all eligibility criteria (36–45).
Szymanski et  al., studying 206 consecutive children with 
postnatally confirmed prenatal HN, reported that patients with 
high-grade HN had a threefold greater risk of UTIs vs. those 
with low-grade, after adjusting for gender and circumcision 
status. Children with high-grade HN had 11.1 infections per 100 
patient-years compared to 3.52 infections per 100 patient-years 
in those with low-grade HN (p = 0.02) (36). Gender, circumci-
sion status, and presence of VUR (all patients with reflux were 
on CAP) were not found to be independent risk factors for UTI 
(36), analysis that may have been limited by the few number of 
UTI events and the retrospective design of their study.
Islek et al. studied a specific group of 84 prenatal HN patients 
with UPJO-like (isolated HN) of different HN grades. The authors 
concluded that CAP did not change the risk of UTI, regardless of 
HN severity, as none of their 84 patients with UPJO-like type 
of HN developed UTI within a median follow-up period of 
18 months (37). Due to the lack of UTI data segregated by HN 
etiology (stratification of UTI rates by isolated HN vs. HUN) in 
most of the included studies in Braga et al.’s systematic review, it 
was not possible to comment on the distinct association between 
UPJO-like dilation and UTI risk, as pointed out by Islek et al. (37). 
Nonetheless, the systematic review did suggest that the pooled 
rate of UTI in patients with HUN was significantly higher than 
that of all children with high-grade HN (34 vs. 23%, p < 0.05). 
Gimpel et al. corroborated these findings by noting an overall 45% 
UTI rate in 49 patients with 56 primary obstructive megaureters. 
These authors observed a 50% absolute risk reduction in UTI rate 
of children on CAP compared to those not receiving prophylaxis 
(94 vs. 42%, p < 0.01) (38).
Herz et  al. observed a 22% UTI rate in 405 patients with 
prenatal HN. These authors found a significantly lower UTI rate 
in children receiving CAP compared to those not on antibiotics 
(7.9 vs. 18.7%, p = 0.02). In addition, based on their multivariate 
analysis, presence of ureteral dilation, high-grade VUR, and UVJ 
obstruction (primary megaureter) were independent risk factors 
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for development of UTI (39). More specifically, children with ure-
teral dilation >11 mm not receiving CAP had a 5.54 (OR = 5.54; 
CI = 3.15–7.42, p = 0.001)-fold increased risk of fUTI compared 
to those on CAP (39).
A study by Duzenli et al. captured by our updated gray litera-
ture search, showed a 22% UTI rate in infants with postnatally 
confirmed prenatal HN, even though only 36% of the entire 
group of 136 patients were on CAP (40).
Sencan et al. conducted a prospective review of 760 patients 
with mild prenatal HN, defined in the study as an anterior–pos-
terior pelvic diameter of 7–10 mm. Of the 692 patients who had 
complete clinical data, 23 (3.3%) developed a UTI at mean and 
median ages of 7.4 and 3 months, respectively. Eighteen (78.3%) 
of the 23 patients underwent a VCUG and two (8.7%) had high-
grade VUR. Uncircumcised males had a 7.8 times greater risk 
of developing UTI compared to those who were circumcised 
(p < 0.001) (41).
A prospective observational study conducted by Di Renzo 
et  al. examined 47 children with 58 primary non-refluxing 
megaureters and found an overall rate of fUTI of 15%, with 6 
(13%) of these patients requiring hospitalization. The majority of 
fUTIs developed after 6 months of age, contradictory to much of 
the current literature (42).
A recent study by Zee et al. examined patients prospectively 
enrolled in the SFU HN registry to determine incidence and 
factors associated with UTI in children with prenatal HN. Two 
hundred and thirteen patients (154 males) from four medical 
centers were enrolled, with 9% of patients developing a UTI. 
Mulitvariate analysis identified females (OR 7.3, CI 2.2–22, 
p < 0.001), uncircumcised males (p < 0.01), and presence of renal 
cyst (p < 0.05) as significant risk factors for UTI. Interestingly, 
this cohort provided no evidence of protective effect regarding 
CAP administration in patients with HN (43).
Finally, in a prospective review of 80 patients with primary 
non-refluxing megaureter, Braga et al. observed a 34% fUTI rate. 
Using a Cox regression analysis, they found that uncircumcised 
males (HR = 3.4, 95% CI: 1.1–10.7, p = 0.04) and lack of CAP 
(HR = 4.1, 95% CI: 1.3–12.7, p = 0.01) were independent risk fac-
tors for the development of fUTI in this subgroup of prenatal HN 
patients (44). Similarly, a recent review article on HN identified 
circumcision as having a protective effect in preventing UTIs, and 
hence, suggested that either performing elective circumcision 
or prescription of CAP be considered as part of the postnatal 
management plan for prenatal HN patients (45).
sTeP 4 – reVieWing YOUr OWn 
PracTice
Given the paucity of data on UTI risk factors in the HN literature 
and the inability of our systematic review to provide strong 
evidence regarding the association between patient character-
istics and UTI, we sought to review the postnatal management 
of children with prenatal HN at our own institution, aiming to 
specifically explore the following a priori identified variables: HN 
grade, gender, circumcision status, HN etiology/type, use of CAP, 
and VUR status (46). Following  institutional ethics approval 
(10-594-C), this study reviewed available data on 376 patients, 
99 females and 277 males, with postnatally confirmed prenatal 
HN who were seen in a single pediatric urology outpatient clinic. 
Even though retrospective in nature, we sought to improve the 
accuracy of diagnosing UTIs by only including events that had a 
positive urine culture with >100000 cfu of a single microorgan-
ism in a catheterized specimen and associated with temperature 
≥38°C. CAP was prescribed more often to female infants vs. males 
(71 vs. 57%, p < 0.01), those with high- vs. low-grade HN (70 vs. 
55%, p < 0.01), and to children with VUR vs. those without reflux 
(96 vs. 51%, p < 0.01). Circumcision status was not observed to 
play a role in changing CAP prescribing patterns (47).
Similarly to others (5, 36), we confirmed that patients with 
high-grade HN were at a higher risk of UTI when compared 
to those with low-grade (adjusted OR 2.4, 95% CI: 1.3–4.6). 
In addition, this study was the first to clearly demonstrate that 
circumcision status is an important confounder of the association 
between gender and UTI risk in this patient population. The risk 
of UTI was three times higher in females (adjusted OR: 3.2; 95% 
CI: 1.0–10.2) and uncircumcised males (adjusted OR: 3.6; 95% 
CI: 1.2–11.2) compared to circumcised boys. As such, the relative 
risk of UTI in female vs. male infants in any HN population is 
bound to depend on the proportion of males who are circumcised 
and simply segregating by gender without consideration of this 
important covariate is bound to make analyses incomplete and 
potentially erroneous (46). Three other studies shared similar 
findings, asserting that the foreskin on uncircumcised males 
and external genitalia in baby girls harbors pathogenic bacteria, 
explaining the increased UTI risk (2, 3, 47).
In addition, we also observed a threefold higher UTI rate in 
patients with HUN compared to those with isolated HN (i.e., 
“UPJO-like”) (23 vs. 7%, p  =  0.03). These results were sup-
ported by at least two previous studies, which hypothesized that 
urinary stasis in a dilated collecting system or tortuous ureter 
would facilitate bacteria colonization and growth, providing a 
conceptual basis for infection risk (6, 33). Interestingly, contrary 
to the systematic review results, our retrospective study found 
no association between CAP use and UTI rates. Such finding, 
which differs from prior studies reporting benefit in UTI preven-
tion (39), exemplifies uncertainty over the real efficacy of this 
prophylactic intervention in patients with prenatal HN. The main 
limitation of our retrospective study was the inability to obtain 
detailed information on all patients. For example, compliance to 
CAP could not be assessed. If CAP truly impacted UTI rates, then 
non-compliance would lead to a reduced benefit margin between 
groups (type II error), even though a true difference exists. Not 
adjusting for such a confounder may have biased the results, 
changing a treatment effect from positive to negative or no effect. 
This highlights the importance of adjusting for clinically relevant 
confounders with more stringent research strategies (13–15).
sTeP 5 – lOngiTUDinal PrOsPecTiVe 
sTUDY
Learning from the shortcomings of our previous analyses, we 
sought to verify the impact of gender, circumcision status, HN 
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grade, VUR status, type of HN, and CAP use on rate and time to 
UTI in a prospective fashion (48). By doing so, we confirmed that 
females and uncircumcised males had a significantly higher UTI 
risk compared to that of circumcised males (HR for females = 3.4, 
95% CI: 1.2–9.2; HR for uncircumcised males =  3.2, 95% CI: 
1.2–8.4; p =  0.02). Likewise, Herndon et  al. have shown that 
uncircumcised males experienced a fourfold higher risk of UTI 
compared to circumcised boys with prenatal HN (19). In addi-
tion, as indicated in the systematic review (5) and in a recent 
study by Herz et al. (39), we also found that CAP reduced the 
risk of UTIs in children with postnatally confirmed prenatal HN 
when compared to those not receiving antibiotics (HR = 5.2; 95% 
CI: 2.7–10.0; p < 0.01).
Although prospective, this study was observational (ethics 
approval: 13-162-D). Thus, recommendation to obtain a VCUG 
in our cohort was based on physicians’ discretion, practice that is 
variable considering that its value remains controversial (19, 20, 
33, 49). Nevertheless, we documented that diagnosis of VUR was 
strongly associated with development of UTIs in this population 
(HR = 20.8; 95% CI: 10.2–42.3; p < 0.01). This is clinically relevant 
as it establishes VUR as an important risk factor for UTI, not only 
for children diagnosed following a first episode of fUTI (50) but 
also in asymptomatic patients identified solely due to the presence 
of prenatal HN. While some authors caution the indication of 
VCUG in all children after development of the first fUTI (51), 
others have reported that a VCUG can be safely performed in 
high-grade HN patients without increasing the risk of UTI (52).
As it occurs with any observational study, limitations innate 
to the nature of the study design do not allow controlling for 
unknown confounding variables, which may lead to an over-
estimation of the overall UTI rate. Therefore, as a logical next 
step to consolidate the evidence regarding effectiveness of CAP 
in reducing UTIs in children with prenatal HN, we decided to 
conduct a RCT comparing prophylactic antibiotic to placebo in 
this population.
sTeP 6 – Designing a FeasiBiliTY 
PilOT sTUDY
Randomized controlled trials are considered as the gold standard 
for evaluating the effectiveness of an intervention, thus ranking 
among the highest levels of evidence when properly conducted. 
However, doing an RCT that involves vulnerable groups, such as 
children, poses an enormous recruitment challenge. Difficulties 
in recruiting and guaranteeing compliance for a large planned 
sample of patients often demands expanding the number of study 
sites, which adds to costs for coordination. With the ultimate goal 
of conducting a large multicenter RCT, we sought to first assess its 
feasibility. Thus, our aim was to conduct a pilot trial on the effect 
of CAP on fUTI rate in infants with high-grade HN. More specifi-
cally, our feasibility study focused on determining barriers and 
realistic expectations for recruitment rate, determining an event 
rate within the confines of an experimental study, and assessing 
medication compliance and optimal outcome measures.
Following institutional ethics approval (09-255) patients 
1–5  months old with SFU grade III/IV isolated HN or HUN 
(ureteral caliber ≥7 mm), confirmed by postnatal ultrasound, 
and who had a VCUG to rule out VUR were included in the 
study. Children with low-grade HN were excluded because of 
their minimal risk of UTI (5) and to avoid unnecessary radia-
tion exposure. Computer-generated, blocked randomization 
allocated patients on a 1:1 ratio to Trimethoprim or placebo. 
Participants, medical staff, research assistants and outcome 
assessors were blinded to the type of intervention received (53).
Of the 301 HN patients screened, 220 (73%) were not eligible to 
participate in the study. The most common reasons for exclusion 
were age at presentation >5 months (49%), low-grade HN (33%), 
and VUR (10%). On the other hand, of the 81 eligible children, 
46 (57%) were successfully recruited, with all but 5 followed up to 
study completion (2 missed randomization window and 3 with-
drew during the trial). Six patients (20.7%) developed fUTI over a 
mean follow-up period of 8.4 months. UTI was significantly more 
likely to occur in children with HUN than in those with isolated 
HN (26 vs. 4%, p = 0.02). Overall, high-level of compliance was 
demonstrated with 95% medication compliance and 98% clinic 
follow-up compliance rates, respectively (53).
This high adherence to study protocol provided us the confi-
dence necessary to run a definitive trial to test the effectiveness of 
CAP in reducing UTIs in patients with prenatal high-grade HN. 
More importantly, this pilot trial was invaluable in highlighting 
the need to improve patient recruitment, which was achieved by 
extending the patient age limit to 7 months and by collaborating 
with other centers to create a multicenter study.
sTeP 7 – cOsT-UTiliY analYsis
Through the development of a probabilistic decision model, we 
evaluated whether prescription of CAP in infants with high-grade 
HN within the first 2 years of life to prevent fUTIs is an efficient 
use of health-care resources. The model estimated clinical out-
comes, expected costs, and quality-adjusted life years (QALYs) 
related to two management scenarios in infants with high-grade 
HN: use of CAP and monitoring without CAP (54).
The base case for this analysis was set to be an infant with SFU 
III or IV HN, without VUR and with an APD of ≥15 mm over 
a 2-year time horizon. Overall, the use of CAP for prevention 
of UTI in infants with SFU grade III/IV HN cost CAD$1571.19 
compared to CAD$1956.44 when CAP was not used. This 
produced an estimated cost reduction of $385.25, a decrease in 
outpatient UTIs by 0.21 infections, and produced 0.0001 more 
QALYs when compared to no CAP (54).
Overall, this probabilistic decision model provided evidence 
that across all three outcomes, CAP was a more efficient expendi-
ture than no CAP for the prevention of UTI in infants with high-
grade HN within the first 2 years of life.
These results were deemed promising, and when coupled 
with the pilot RCT data, further encouraged us to conduct the 
definitive RCT on use of CAP in this population. This cost-utility 
analysis, when combined with the results of the definitive RCT, 
will allow an evidence-based health policy statement regarding 
the effectiveness of CAP in the prevention of UTIs in infants with 
high-grade HN to be developed.
TaBle 1 | Baseline demographic characteristics of enrolled patients in 
the definitive rcT.
Variable no. of patients
n = 102 (%)
Female 17 (17)
Males
 Uncircumcised 50 (49)
 Circumcised 35 (34)
Hydronephrosis side
 Lt 64 (63)
 Rt 25 (24)
 Bilat 13 (13)
SFU hydronephrosis grade
 III 71 (70)
 IV 31 (30)
Hydronephrosis etiology
 UPJO-like (isolated hydronephrosis) 71 (70)
 Primary megaureter (hydroureteronephrosis) 29 (28)
 UPJ + UVJ 2 (2)
  Tortuous ureter 18 (58)
  Not tortuous ureter 13 (42)
Hydronephrosis management
 Conservative 79 (77)
 Surgery 23 (23)
  Pyeloplasty 18 (78)
  Distal ureterostomy 1 (4)
  Ureterocystostomy 4 (18)
1035 
Patients 
Screened  
216 (21%) 
 Eligible 
102 (47%) 
Enrolled 
15 (15%) 
Active  
9 (9%)  
Withrew from 
Trial 
78 (76%) 
Completed Trial 
41 (52%) 
Completed 12 months 
follow-up 
24 (31%) 
Hydronephrosis 
resolved (<grade II) 
10 (13%) 
Developed UTI 
3 (4%) 
Hydronephrosis 
resolved after surgery 
8 (4%)  
Pending 
Enrollment 
2 (1%)  
Missed 
104 (48%) 
Declined 
55 (53%) 
Not interested in 
study 
28 (27%) 
Did not want CAP 
11 (10%)  
Wanted CAP 
5 (5%)  
Did not want to be 
blinded 
5 (5%)  
Other 
3 (0.3%) 
 Pending Eligibility 
816 (79%)  
Not Eligible 
FigUre 1 | Flow diagram of all screened patients.
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sTeP 8 – DeFiniTiVe ranDOMiZeD 
PlaceBO cOnTrOlleD Trial
A total of 80 participants per arm were needed to power the 
analysis for the definitive trial at 80%, assuming an alpha error 
of 5% and a conservative estimate of 20–30% event rate in the 
placebo group and 10% in the antibiotic group (49).
Of 1035 infants with prenatal HN screened thus far, 216 (21%) 
have met eligibility criteria. Of these, 104 (48%) declined to par-
ticipate. Main reasons for refusal were lack of any parental interest 
in a research study (n = 55; 53%) and parental unwillingness to be 
blinded to the study medication (n = 44; 42%). Thus, ultimately 
102 (47%) children were recruited (Figure 1).
Of patients enrolled in the study, 85 (83%) were males, of 
which, 35 were not circumcised (34%); 31 (30%) had SFU Grade 
IV HN, and 13 (13%) had bilateral urinary tract dilatation. 
Overall, 71 patients (70%) had UPJO-like and 29 (28%) primary 
megaureter (Table 1). Mean age at randomization was 3 months 
(SD = 1.7), with a median of 2.3 months (0–7 months).
Fifteen (15%) participants are still on active follow-up and 9 
(9%) withdrew during the study course. Of the 78 (76%) who 
completed the trial, 41 (52%) completed the required 12-month 
follow-up without development of fUTI; 24 (31%) finished early 
due to resolution of HN; 3 (4%) resolved following surgery; and 
10 (13%) developed the primary outcome.
The fUTI rate in the definitive RCT was substantially lower 
than the pooled UTI rate derived from our systematic review (13 
vs. 25%, p < 0.05). Figure 2 displays UTI rates stratified by CAP 
use in patients with high-grade HN across different types of study 
design. Interestingly, 8/10 (80%) fUTIs in the definitive trial, 
occurred in uncircumcised boys as seen in Table 2. Similarly to 
our pilot data (49), patients with HUN had a sixfold higher UTI 
rate than those with isolated HN (Figure 3).
TaBle 2 | characteristics of 10 participants with febrile UTis.
Patient – sex age (months) hn side hn grade hn etiology Ureteral diametera (mm) circumcision 
status
surgery
1 – M 6.0 Bilat III HUN 10 No No
2 – F 5.5 Bilat IV HUN 8 N/A No
3 – M 7.0 Lt III UPJO Not dilated No Pyeloplasty
4 – M 11.4 Lt III HUN 12 No No
5 – M 8.1 Lt IV HUN 20 No Ureterostomy and pyeloplasty
6 – M 6.3 Lt III HUN 10 No No
7 – M 5.1 Lt IV UPJ + UVJ 10 No Pyeloplasty and ureterocystostomy
8 – M 9.0 Lt III UPJO Not dilated No No
9 – M 3.0 Rt IV HUN 14 No No
10 – M 4.6 Rt IV HUN 15 Yes Ureterocystostomy
aUreteral diameter was obtained from the ultrasound performed around the time of the febrile UTI.
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FigUre 2 | UTi rates in patients with high-grade hn across different types of study design. *Continuous antibiotic prophylaxis (CAP) use in hydronephrosis 
(HN) patients is unknown due to blinding. †Ongoing trial.
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FigUre 3 | UTi rates in patients with hn stratified by etiology (UPJO-like vs. primary megaureter). *Urinary tract infection rates in patients with UPJO-like 
was not reported due to paucity of data. †Study only included patients with Primary Megaureter. ‡Ongoing trial.
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No side effects were associated with the use of the Trimethoprim 
according to the Data Safety Monitoring Board (DSMB) to date.
Of 78 patients who completed the study, only 1 (1.3%) was 
non-compliant (meaning that the child received the medication 
less than 75% of the time) based on information obtained from 
returned medication logs at follow-up clinic visits. Overall, three 
(3.8%) children missed one of the four required follow-up clinic 
visits. This high medication compliance and minimal loss to 
follow-up attested to the feasibility of this RCT.
FUTUre DirecTiOns
Despite controversial guidelines surrounding the management 
of prenatal HN, we have outlined the critical steps leading to a 
definitive multicenter RCT. While such studies are considered the 
gold standard in research, randomization alone does not warrant 
high methodological quality (55). Loss to follow-up can be a seri-
ous threat to the validity of studies. We, therefore, made it a prior-
ity to authenticate the feasibility of the ALPHA study through 
a pilot and interim descriptive analyses of the definitive study. 
Now that we have established true feasibility, our next step is to 
warrant a large sample size to ensure we obtain adequate power 
to properly answer the question regarding the efficacy of CAP 
in patients with prenatal HN. Large sample sizes are beneficial in 
that they enable investigators to detect small differences between 
treatments, minimizing findings due to chance (55). However, a 
single tertiary center simply does not have the necessary patient 
volume to complete the study in a timely manner (17% eligibility 
rate). For that reason, collaboration with multiple sites is key. 
Ultimately, the expansion of our collaborative network is driven 
by the need to provide meaningful data that guide clinicians and 
benefits patients.
A decline from 25 to 13% in the UTI rate of patients with high-
grade HN was observed as the hierarchy of evidence progressed 
from observational studies to RCTs. This demonstrates that study 
designs lacking randomization, allocation concealment, or other 
strategies to minimize bias are more susceptible to overestima-
tion of treatment effects. This finding highlights the importance 
of conducting properly powered, high-quality RCTs to answer 
clinically meaningful questions, such as the one regarding the 
effectiveness of CAP to prevent UTIs in infants with prenatal HN.
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